Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05649670

Acute Stroke: Prehospital Versus In-HospitAL Initiation of Recanalization Therapy- ASPHALT

ASPHALT is an academic-driven open-label randomized controlled trial of Mobile Stroke Unit (MSU) deployment versus standard care in France, with blinded assessment of efficacy endpoints. 450 patients with confirmed acute ischemic stroke will be recruited over a 3-year period, with 3-month follow-up.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

AP-HP - hôpital Raymond Poincaré, Garches, France

Loading trial locations.

About this study

Instead of the traditional approach of waiting until the patient arrives at the hospital to perform brain imaging and start reperfusion therapies, mobile stroke units (MSUs; ambulances equipped with a CT scanner) now allow pre-hospital initiation of intravenous thrombolysis (IVT). Two large non-randomized clinical trials (B_PROUD & BEST-MSU) have recently shown that MSU use leads to improved functional outcomes at 3 months in specific settings. However, MSUs have been criticized because of their cost and a lack of evidence of a significant reduction in the time between symptom onset and mechanical thrombectomy, which is the cornerstone of treatment of patients with large vessel occlusion.

We hypothesized that compared to usual care, the deployment of a MSU would result in an incremental cost-utility ratio ≤50,000 euros per QALY in the lifetime horizon, even in an area with many thrombectomy-capable centers..

Academic-driven open-label randomized controlled trial of Mobile Stroke Unit (MSU) deployment versus standard care in France, with blinded assessment of efficacy endpoints. Randomization will be performed on an individual patient basis (randomization of MSU deployment at dispatch). 450 patients with confirmed acute ischemic stroke (emergency call ≤6 hours after onset) will be recruited over a 3-year period, with 3-month follow-up. Costs and clinical outcomes will be collected prospectively during the study period and used to extrapolate the incremental cost-utility ratio over a lifetime horizon.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Emergency call to one of the two following emergency medical service (EMS) dispatch centers : SAMU (Service d'Aide Médicale Urgente) or BSPP (Brigade des Sapeurs Pompiers de Paris), between 08:00 and 18:00, 5 days a week (Monday to Friday).
  • Suspected acute stroke according to a dispatcher stroke identification algorithm, adapted from the ROSIER scale
  • Symptom onset-to-randomization time ≤ 6h
  • Patient located within the predefined catchment area of the MSU
  • MSU available at the time of the EMS call
  • Informed consent (as approved by the ethics committee, informed consent will be obtained after randomization: at the arrival of the MSU (intervention group), or at hospital arrival (control group))

Exclusion criteria

  • Patient confined to be more than 50% of waking hours
  • Unknown or uncertain onset time (e.g. wake-up stroke)
  • Medical history of epilepsy
  • Recent epileptic seizure (<12 hrs)
  • Suspicion of pregnancy
  • Parturient or breastfeeding woman
  • Patient already participating in another interventional study, which could influence the mRS at 3 months.
  • Patient under guardianship or curatorship
  • Patient not affiliated to French Social Security

Treatment and study plan

Mobile Stroke Unit deployment

Other

Deployment of an MSU + conventional ambulance, allowing prehospital CT-scan imaging with intracranial CT angiography. This will allow prehospital intravenous thrombolysis and optimal triage (i.e. accurate identification of patients with large vessel occlusion, who are eligible for mechanical thrombectomy).

Other names: Mobile Stroke Unit management

Primary outcomes

  1. Incremental Cost-Utility Ratio (ICUR)

    Time frame: 3 months

    ICUR in the lifetime horizon, based on extrapolated results of the Modified Rankin Scale (mRS) at 3 months and incremental costs prospectively collected during the first 3 months

  2. Key secondary outcome: Modified Rankin Scale (mRS) at 3 months

    Time frame: 90 +/- 14 days

    Modified Rankin scale, assessed in a blinded fashion (range, 0 to 6, with 0 indicating no disability, 3 indicating moderate disability, and 6 indicating death)

Secondary outcomes

  1. ICUR at 3 months

    Time frame: 90 +/- 14 days

    Incremental Cost-Utility Ratio based on results of the Modified Rankin Scale (mRS) at 3 months and incremental costs prospectively collected during the first 3 months

  2. ICUR at 5 years

    Time frame: 5 years

    Incremental Cost-Utility Ratio based on extrapolated results of the Modified Rankin Scale (mRS) at 3 months and incremental costs prospectively collected during the first 3 months

  3. Time from symptom onset to intravenous thrombolysis (IVT)

    Time frame: up to 4.5 hours from symptom onset

    Time from symptom onset to IVT bolus

  4. Time from symptom onset to mechanical thrombectomy (MT)

    Time frame: up to 24 hours from symptom onset

    Time from symptom onset to arterial puncture

  5. Time from alarm to IVT

    Time frame: up to 4.5 hours from symptom onset

    Time from ambulance dispatch to IVT bolus

  6. Time from alarm to MT

    Time frame: up to 24 hours from symptom onset

    Time from ambulance dispatch to arterial puncture

  7. Death within 3 months after randomization

    Time frame: Within 90 days after randomization

    All-cause mortality

  8. Death within 7 days after randomization

    Time frame: Within 7 days after randomization

    All-cause mortality

  9. Proportion of ischemic stroke patients treated with IVT

    Time frame: up to 4.5 hours from symptom onset

    Proportion of patient treated with IVT among those with confirmed ischemic stroke

  10. Proportion of ischemic stroke patients with MT

    Time frame: up to 24 hours from symptom onset

    Proportion of patient treated with MT among those with confirmed ischemic stroke

  11. Proportion of ischemic stroke patients treated with IVT within 60 minutes of symptom onset

    Time frame: within 60 minutes of symptom onset

    Golden hour thrombolysis

  12. Symptomatic intracranial hemorrhage

    Time frame: Within 36 hours from randomization

    ECASS-2 definition

Study contacts

Contact information is provided by the study sponsor or research team.

Khaoussou SYLLA, MD, PhD

CONTACT

[email protected]

+33 (01) 45 65 76 78

Malha BERRAH, MSc

CONTACT

[email protected]

+33 (0)1 56 09 58 22

Sponsors and collaborators

Lead sponsor

Centre Hospitalier St Anne

Other

Collaborators

  • Assistance Publique - Hôpitaux de Paris
  • Ministry of Health, France

Registry information

Official study title

Prehospital Initiation of Reperfusion Therapy for Acute Ischemic Stroke: Randomized Medico-economic Evaluation of a Mobile Stroke Unit.

Acronym: ASPHALT

Important dates

Study start
2023
Primary completion
2026
Study completion
2027
First posted
Dec 14, 2022
Registry last updated
Feb 1, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.